LYN and B-cell chronic lymphocytic leukemia: We also tested the effect of two kinase inhibitors, Bafetinib (dual BCR-Abl/Lyn inhibitor) and Ibrutinib (Btk inhibitor), known to reduce neoplastic B cell viability in vitro [23], on CLL B cells in presence of MSCs.